ImageneBio (IMA) Restructuring Costs (2024 - 2025)
ImageneBio's (IMA) quarterly Restructuring Costs came in at $2.8 million in Q3 2025, up 586.51% year-over-year from $415000.0 in Q3 2024, and up 822.01% quarter-over-quarter from $309000.0 in Q2 2025.
Powered by 
Analysis
ImageneBio (IMA) Restructuring Costs (2024 - 2025) Analysis & Trends
ImageneBio has disclosed Restructuring Costs across 2 years of filings, most recently posting $2.8 million for Q3 2025.
- In Q3 2025, Restructuring Costs rose 586.51% year-over-year to $2.8 million; the TTM figure through Sep 2025 stood at $6.7 million (changed N/A YoY), while the FY2024 annual figure was $4.4 million, changed N/A from the prior year.
- Restructuring Costs came in at $2.8 million for Q3 2025 at ImageneBio, up from $309000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $2.8 million in Q3 2025 to a low of $309000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | ImageneBio | 42.89 Mn | -92.46 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 2.85 Mn |
| Jun 30, 2025 | 309,000.00 |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 2.08 Mn |
| Sep 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 683,000.00 |
| Mar 31, 2024 | 2.60 Mn |